


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| | | | |
|--|--|--|--|
| <p style="text-align: center;">Licensee</p> <p>1. Liberty Hospital Nuclear Medicine Department</p> <p>2. 2525 Glenn W. Hendren Drive Liberty, MO 64069-1002</p> | | <p>In accordance with letter dated October 18, 2017.</p> | <p>4. Expiration Date: April 30, 2021</p> |
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Palladium-103 permitted by 10 CFR 35.400</p> <p>E. Uranium- depleted in Uranium-235</p> | | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Theragenics Corporation, Model TheraSeed 200)</p> <p>E. Metal</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 1 curie total</p> <p>E. 12 kilograms per source and 48 kilograms total</p> |
| <p>2. 2525 Glenn W. Hendren Drive Liberty, MO 64069-1002</p> | | <p>3. License number: 24-16178-01 is amended in its entirety to read as follows:</p> | <p>5. Docket No.: 030-10532 Reference No.:</p> |
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Palladium-103 permitted by 10 CFR 35.400</p> <p>E. Uranium- depleted in Uranium-235</p> | | <p>9. Authorized use</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</p> <p>E. Shielding in ADAC Laboratories MCD-AC attenuation correction system.</p> | |



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-16178-01

Docket or Reference Number

030-10532

Amendment No. 47

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:
- A. 2525 Glenn W. Hendren Drive, Liberty, Missouri, 64068
- B. 2521 Glenn W. Hendren Drive, Liberty, Missouri, 64068
11. The Radiation Safety Officer (RSO) for this license is Joseph Caresio, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as either authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|--|
| Robert C. Newth, M.D. | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 |
| Robert A. MacNaughton, II, M.D. | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 |
| Richard A. Morrison, M.D. | 10 CFR 35.400 |
| Gordon D. Stillie, M.D. | 10 CFR 35.400 |
| Scott C. Cozad, M.D. | 10 CFR 35.400 |
| John I. Halloran, M.D. | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 |
| Timothy G. Raveill, M.D. | 10 CFR 35.100,10 CFR 35.200 |
| Randall C. Newth, M.D. | 10 CFR 35.100,10 CFR 35.200 |
| Michael P. Green, D.O. | 10 CFR 35.100,10 CFR 35.200 |
| John Brian Pope, M.D. | 10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131) |
| Joseph Caresio, M.D. | 10 CFR 35.100,10 CFR 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-16178-01

Docket or Reference Number

030-10532

Amendment No. 47

Authorized User(M.D.,D.O.,etc.)

Dwarakraj Soundarraj, M.D.

Christine Keesling, M.D.

Daniel H. Dunker, M.D.

Martina Milcevic, M.D.

Andrew Harmon, M.D.

Material and Use


10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV)



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-16178-01Docket or Reference Number
030-10532

Amendment No. 47

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 21, 2010 (ML102780663)
 - B. Facsimile dated March 16, 2011 (ML110750577)
 - C. Facsimile dated March 17, 2011 (ML110760650)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 31, 2018By: Jennifer L. Bishop
Jennifer L. Bishop
Region 3